Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 IncyteCharles River Laboratories InternationalPPDExact SciencesPRA Health Sciences
SymbolNASDAQ:INCYNYSE:CRLNASDAQ:PPDNASDAQ:EXASNASDAQ:PRAH
Price Information
Current Price$82.66$324.59$46.20$127.64$161.50
52 Week RangeHoldBuyHoldBuyHold
MarketRank™
Overall Score1.71.31.81.81.4
Analysis Score2.21.42.23.41.1
Community Score3.12.43.33.12.6
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score1.31.31.90.61.9
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyHold
Consensus Price Target$101.50$254.71$41.91$150.33$121.29
% Upside from Price Target22.79% upside-21.53% downside-9.29% downside17.78% upside-24.90% downside
Trade Information
Market Cap$18.18 billion$16.24 billion$16.21 billion$21.99 billion$10.44 billion
Beta0.961.12N/A1.641.24
Average Volume1,291,649319,9382,104,8381,716,192751,325
Sales & Book Value
Annual Revenue$2.16 billion$2.62 billion$4.03 billion$876.29 million$3.07 billion
Price / Sales8.426.224.0224.633.40
Cashflow$2.23 per share$12.90 per shareN/AN/A$8.65 per share
Price / Cash37.0625.17N/AN/A18.67
Book Value$12.06 per share$33.45 per shareN/A$17.62 per share$17.23 per share
Price / Book6.859.707.249.37
Profitability
Net Income$446.91 million$252.02 million$47.82 million$-83,990,000.00$243.02 million
EPS$2.23$6.73$0.98($1.49)$4.80
Trailing P/E RatioN/A54.10308.00N/A47.22
Forward P/E Ratio30.8436.3933.48N/A31.67
P/E Growth0.982.191.90N/A2.26
Net Margins-13.62%10.68%0.21%-25.27%7.09%
Return on Equity (ROE)-13.66%22.41%-11.06%-11.71%22.21%
Return on Assets (ROA)-9.98%7.66%2.75%-6.74%7.04%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%1.04%N/A0.68%0.95%
Current Ratio3.56%1.45%1.09%6.35%1.13%
Quick Ratio3.53%1.22%1.09%6.04%1.13%
Ownership Information
Institutional Ownership Percentage91.37%92.30%68.82%90.39%96.14%
Insider Ownership Percentage16.10%1.90%N/A1.80%1.30%
Miscellaneous
Employees1,77318,40026,0004,80018,100
Shares Outstanding219.84 million50.21 million350.43 million169.09 million64.54 million
Next Earnings Date5/4/2021 (Confirmed)5/4/2021 (Confirmed)4/27/2021 (Confirmed)5/4/2021 (Confirmed)4/29/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
PRA Health Sciences (PRAH) Surges 3.8%: Is This an Indication of Further Gains?PRA Health Sciences (PRAH) Surges 3.8%: Is This an Indication of Further Gains?
finance.yahoo.com - April 16 at 9:37 AM
PRA Health Sciences At Top Of Buy Range On Follow-up MovePRA Health Sciences At Top Of Buy Range On Follow-up Move
finance.yahoo.com - April 15 at 11:25 PM
PRA Health Sciences, Inc. (NASDAQ:PRAH) Short Interest UpdatePRA Health Sciences, Inc. (NASDAQ:PRAH) Short Interest Update
americanbankingnews.com - April 15 at 3:28 PM
PRA Health Sciences (NASDAQ:PRAH) Reaches New 52-Week High at $160.20PRA Health Sciences (NASDAQ:PRAH) Reaches New 52-Week High at $160.20
americanbankingnews.com - April 15 at 11:58 AM
SHAREHOLDER ALERT: WeissLaw LLP Reminds BPFH, PRAH, TPCO, and TLND Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: WeissLaw LLP Reminds BPFH, PRAH, TPCO, and TLND Shareholders About Its Ongoing Investigations
finance.yahoo.com - April 14 at 12:22 PM
PRA Health and Merck KGaA team up for human growth hormone treatment systemPRA Health and Merck KGaA team up for human growth hormone treatment system
seekingalpha.com - April 9 at 8:12 AM
$1.35 Earnings Per Share Expected for PRA Health Sciences, Inc. (NASDAQ:PRAH) This Quarter$1.35 Earnings Per Share Expected for PRA Health Sciences, Inc. (NASDAQ:PRAH) This Quarter
americanbankingnews.com - April 9 at 12:10 AM
PRA Health Sciences (NASDAQ:PRAH) Hits New 12-Month High at $158.32PRA Health Sciences (NASDAQ:PRAH) Hits New 12-Month High at $158.32
americanbankingnews.com - April 8 at 12:12 PM
PRA Health Sciences (NASDAQ:PRAH) Reaches New 1-Year High at $155.27PRA Health Sciences (NASDAQ:PRAH) Reaches New 1-Year High at $155.27
americanbankingnews.com - April 1 at 11:40 AM
PRA Health Sciences (NASDAQ:PRAH) Lifted to Hold at Zacks Investment ResearchPRA Health Sciences (NASDAQ:PRAH) Lifted to Hold at Zacks Investment Research
marketbeat.com - March 30 at 1:24 PM
Why Is PRA Health Sciences (PRAH) Down 0.7% Since Last Earnings Report?Why Is PRA Health Sciences (PRAH) Down 0.7% Since Last Earnings Report?
finance.yahoo.com - March 26 at 3:03 PM
PRA Health Sciences, Inc.: PRAs Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical ProgramsPRA Health Sciences, Inc.: PRA's Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
finanznachrichten.de - March 24 at 12:57 PM
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease ...PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease ...
apnews.com - March 24 at 12:57 PM
PRA Health (PRAH) Unveils Toolkit for Rare Disease PatientsPRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
finance.yahoo.com - March 23 at 10:29 AM
PRA Health Sciences toolkit to identify, mitigate rare disease risksPRA Health Sciences toolkit to identify, mitigate rare disease risks
thesundaily.my - March 23 at 5:28 AM
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical ProgramsPRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
finance.yahoo.com - March 22 at 7:20 PM
Investigation announced for Investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) over TakeoverInvestigation announced for Investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) over Takeover
openpr.com - March 20 at 7:03 PM
PRA Health Sciences (NASDAQ:PRAH) PT Raised to $155.00 at MizuhoPRA Health Sciences (NASDAQ:PRAH) PT Raised to $155.00 at Mizuho
marketbeat.com - March 19 at 11:53 AM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, MIK, WSFS, TLND, SVBI; Shareholders are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, MIK, WSFS, TLND, SVBI; Shareholders are Encouraged to Contact the Firm
finance.yahoo.com - March 12 at 12:18 AM
PRA HEALTH SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in PPRA HEALTH SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in P
us.acrofan.com - March 1 at 10:20 PM
PRA HEALTH SCIENCES INVESTOR ALERT by The Former...PRA HEALTH SCIENCES INVESTOR ALERT by The Former...
benzinga.com - March 1 at 10:20 PM
PRA HEALTH SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAHPRA HEALTH SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAH
finance.yahoo.com - March 1 at 10:20 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAHSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAH
prnewswire.com - February 27 at 3:22 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAHSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAH
markets.businessinsider.com - February 27 at 1:47 AM
PRA Health Sciences, Inc. 2020 Q4 - Results - Earnings Call PresentationPRA Health Sciences, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 1:49 PM
Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law FirmMoore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm
finance.yahoo.com - February 26 at 12:52 PM
PRA Health Sciences, Inc. to Host Earnings CallPRA Health Sciences, Inc. to Host Earnings Call
finance.yahoo.com - February 26 at 7:51 AM
DateCompanyBrokerageAction
4/5/2021IncyteMorgan StanleyLower Price Target
2/10/2021IncyteSVB LeerinkDowngrade
1/7/2021IncyteTruistInitiated Coverage
1/4/2021IncyteGuggenheimUpgrade
11/6/2020IncyteBMO Capital MarketsLower Price Target
11/6/2020IncyteRoyal Bank of CanadaLower Price Target
10/15/2020IncyteBank of AmericaLower Price Target
8/9/2020IncyteCowenReiterated Rating
8/6/2020IncyteCredit Suisse GroupLower Price Target
8/4/2020IncyteMizuhoInitiated Coverage
7/28/2020IncyteJPMorgan Chase & Co.Reiterated Rating
7/24/2020IncyteWilliam BlairReiterated Rating
7/17/2020IncyteOppenheimerReiterated Rating
6/16/2020IncyteBenchmarkInitiated Coverage
6/4/2020IncyteArgusBoost Price Target
2/25/2021Charles River Laboratories InternationalDeutsche Bank AktiengesellschaftBoost Price Target
12/16/2020Charles River Laboratories InternationalSmith Barney CitigroupDowngrade
12/16/2020Charles River Laboratories InternationalCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
11/24/2020Charles River Laboratories InternationalKeyCorpBoost Price Target
9/10/2020Charles River Laboratories InternationalJefferies Financial GroupUpgrade
7/21/2020Charles River Laboratories InternationalUBS GroupBoost Price Target
5/8/2020Charles River Laboratories InternationalRobert W. BairdBoost Price Target
4/16/2021PPDEvercore ISIDowngrade
4/16/2021PPDTruist SecuritiesReiterated Rating
3/8/2021PPDBarclaysInitiated Coverage
2/17/2021Exact SciencesStifel NicolausBoost Price Target
1/12/2021Exact SciencesCanaccord GenuityBoost Price Target
10/28/2020Exact SciencesBTIG ResearchBoost Price Target
5/7/2020Exact SciencesCraig HallumLower Price Target
5/4/2020PRA Health SciencesSunTrust BanksBoost Price Target
4/13/2020PRA Health SciencesWolfe ResearchDowngrade
1/10/2020PRA Health SciencesThe Goldman Sachs GroupDowngrade
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.